Dyslipidemia Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

(Albany, USA) DelveInsight's "Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Dyslipidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dyslipidemia market size from 2020 to 2034, segmented by seven major markets. The Dyslipidemia Market Report also covers current Dyslipidemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dyslipidemia market.

To Know in detail about the Dyslipidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia Market Forecast
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Dyslipidemia Market Report:
• The Dyslipidemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In November 2024, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage clinical biopharmaceutical firm developing oral, non-statin medications for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), who do not respond well to existing therapies, today announced positive topline results from its Phase 3 TANDEM clinical trial (NCT06005597). The TANDEM trial will support global regulatory submissions for the 10 mg obicetrapib and 10 mg ezetimibe fixed-dose combination in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors, whose LDL-C remains inadequately controlled despite receiving maximally tolerated lipid-lowering therapy.
• In August 2024, At the European Society of Cardiology (ESC) 2024 meeting, Dr. Erin Michos discussed the success of obicetrapib trials thus far. NewAmsterdam has demonstrated promising results in all Phase II trials, including ROSE2, TULIP, ROSE, and OCEAN, which assessed obicetrapib as both a monotherapy and combination therapy, showing its ability to significantly lower low-density lipoprotein (LDL) levels. The completion of patient enrollment in the Phase III TANDEM trial marks a key milestone towards the potential launch of obicetrapib, bringing NewAmsterdam closer to offering a new treatment option for dyslipidemia, heterozygous familial hypercholesterolemia (HeFH), and/or atherosclerotic cardiovascular disease (ASCVD).
• In July 2024, NewAmsterdam Pharma reported positive results from the first of its four pivotal Phase III trials, demonstrating that its lead cardiovascular candidate, obicetrapib, effectively lowers cholesterol levels. The BROOKLYN trial (NCT05425745) is the initial study in NewAmsterdam's portfolio, focused on assessing obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains inadequately managed despite receiving the maximum tolerated lipid-lowering therapy.
• The most common form of dyslipidemia observed was hypercholesterolemia (total cholesterol level ≥ 5.0 mmol/L), with an average prevalence of 58.2%, ranging from 50% to 67% based on the region.
• The standardized prevalence figures for dyslipidemia in Switzerland, characterized by either self-reported drug use alone or a combination of self-reported drug use and a self-reported diagnosis of dyslipidemia, were 3.7% (95% CI 3.3-4.1%) and 12.2% (95% CI 11.5-12.9%) for women, and 6.3% (95% CI 5.7-6.8%) and 16.9% (95% CI 16.0-17.8%) for men, respectively.
• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others
• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others
• The Dyslipidemia epidemiology based on gender analyzed that females are affected more as compared to males, in case of Dyslipidemia
• The Dyslipidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dyslipidemia pipeline products will significantly revolutionize the Dyslipidemia market dynamics.

Dyslipidemia Overview
Dyslipidemia is a medical condition characterized by abnormal levels of lipids (fats) in the blood, including high levels of low-density lipoprotein (LDL) cholesterol, triglycerides, or total cholesterol, and/or low levels of high-density lipoprotein (HDL) cholesterol. These imbalances increase the risk of cardiovascular diseases such as heart attack and stroke.

Dyslipidemia can be classified as primary (genetic) or secondary (caused by lifestyle factors or other medical conditions). Common risk factors include poor diet, obesity, sedentary lifestyle, smoking, excessive alcohol intake, diabetes, hypothyroidism, and chronic kidney disease. Familial hypercholesterolemia is a genetic form of dyslipidemia that significantly increases cholesterol levels from an early age.

Most individuals with dyslipidemia do not experience noticeable symptoms, making routine blood lipid tests essential for early detection. Diagnosis is typically based on a lipid panel measuring total cholesterol, LDL, HDL, and triglycerides.

Treatment focuses on lifestyle modifications, including a heart-healthy diet (rich in fiber and unsaturated fats), regular exercise, weight management, and smoking cessation. In moderate to severe cases, medications such as statins, fibrates, or PCSK9 inhibitors may be prescribed to lower cholesterol and reduce cardiovascular risk. Long-term management is crucial for preventing complications.

Get a Free sample for the Dyslipidemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dyslipidemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dyslipidemia Epidemiology Segmentation:
The Dyslipidemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Dyslipidemia
• Prevalent Cases of Dyslipidemia by severity
• Gender-specific Prevalence of Dyslipidemia
• Diagnosed Cases of Episodic and Chronic Dyslipidemia

Download the report to understand which factors are driving Dyslipidemia epidemiology trends @ Dyslipidemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dyslipidemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia market or expected to get launched during the study period. The analysis covers Dyslipidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dyslipidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dyslipidemia Therapies and Key Companies
• Pemafibrate (K-877): Kowa Company
• AZD8233: AstraZeneca And Parexel
• Rosuvastatin: AstraZeneca
• GW856553: GlaxoSmithKline
• A3309: Albireo
• TA-8995: Xention Ltd
• Alirocumab: Sanofi
• Muraglitazar: Bristol-Myers Squibb
• Atorvastatin (Lipilou): Chong Kun Dang Pharmaceutical
• MK1903: Merck Sharp & Dohme LLC
• Lapaquistat acetate: Takeda
• PPAR alpha: Eli Lilly and Company

Discover more about therapies set to grab major Dyslipidemia market share @ Dyslipidemia Treatment Landscape
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dyslipidemia Market Drivers
• Increasing global geriatric population
• Increase in the prevalence of lifestyle related and cardiovascular disorders

Dyslipidemia Market Barriers
• Significant proportion of treated patients do not reach recommended treatment goal
• Increase in availability of generic drugs

Scope of the Dyslipidemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others, and others
• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others
• Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and Dyslipidemia emerging therapies
• Dyslipidemia Market Dynamics: Dyslipidemia market drivers and Dyslipidemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dyslipidemia Unmet Needs, KOL's views, Analyst's views, Dyslipidemia Market Access and Reimbursement

To know more about Dyslipidemia companies working in the treatment market, visit @ Dyslipidemia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Dyslipidemia Market Report Introduction
2. Executive Summary for Dyslipidemia
3. SWOT analysis of Dyslipidemia
4. Dyslipidemia Patient Share (%) Overview at a Glance
5. Dyslipidemia Market Overview at a Glance
6. Dyslipidemia Disease Background and Overview
7. Dyslipidemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Dyslipidemia
9. Dyslipidemia Current Treatment and Medical Practices
10. Dyslipidemia Unmet Needs
11. Dyslipidemia Emerging Therapies
12. Dyslipidemia Market Outlook
13. Country-Wise Dyslipidemia Market Analysis (2020-2034)
14. Dyslipidemia Market Access and Reimbursement of Therapies
15. Dyslipidemia Market Drivers
16. Dyslipidemia Market Barriers
17. Dyslipidemia Appendix
18. Dyslipidemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.